Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1.

Signal Transduction and Targeted Therapy
Elizabeth A McNiel, Philip N Tsichlis

Abstract

FGF-2 is overexpressed in a subset of invasive bladder carcinomas and its overexpression correlates with poor prognosis. Analyses of publicly available databases addressing the molecular mechanisms that may be responsible for the poor prognosis of these tumors, revealed that FGF-2 expression correlates positively with the expression of EMT-promoting transcription factors and with changes in gene expression that are characteristic of EMT. The same analyses also revealed that FGF-2 correlates negatively with the expression, mutation and copy number variations of FGFR-3, all of which are associated with non-invasive bladder carcinomas. Finally, they showed that FGF-2 expression correlates with the expression of FGFR-1, the expression of the IIIc variant of FGFR-2 and with the expression of Akt3. The latter observation is significant because our earlier studies had shown that Akt3 regulates FGFR-2 alternative splicing, shifting the balance toward the IIIc relative to the IIIb FGFR-2 splice variant. Since the IIIc variant is recognized by FGF-2, while the IIIb variant is not, we conclude that Akt3 may facilitate the FGF-2 response. FGF-2 is known to promote the expression of KDM2B, which functions in concert with EZH2 to repress the...Continue Reading

References

Jan 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·T MikiS A Aaronson
Feb 3, 1993·Journal of the National Cancer Institute·M NguyenJ Folkman
Apr 8, 2004·Neoplasia : an International Journal for Oncology Research·Daniel R RhodesArul M Chinnaiyan
Aug 20, 2005·Nature Reviews. Cancer·Xue-Ru Wu
Feb 24, 2006·Nature Reviews. Molecular Cell Biology·Jean Paul Thiery, Jonathan P Sleeman
Oct 8, 2008·Molecular and Cellular Biology·Christos PolytarchouPhilip N Tsichlis
Mar 31, 2009·Nature Genetics·Gijs van HaaftenP Andrew Futreal
Apr 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ju-Seog LeeIn-Sun Chu
Jul 19, 2011·PloS One·Bettina FussbroichFelix Hoppe-Seyler
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Dec 14, 2012·Proceedings of the National Academy of Sciences of the United States of America·Wei QiEn Li
Feb 2, 2013·Nature Reviews. Drug Discovery·Sheng YaoLieping Chen
Mar 9, 2013·Nature Reviews. Immunology·Lieping Chen, Dallas B Flies
Apr 4, 2013·Science Signaling·Jianjiong GaoNikolaus Schultz
Oct 8, 2013·Nature Structural & Molecular Biology·Luciano Di Croce, Kristian Helin
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Feb 13, 2014·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey S DamrauerWilliam Y Kim
Dec 13, 2012·ACS Medicinal Chemistry Letters·Sharad K VermaWilliam H Miller
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Dec 24, 2014·Nature Reviews. Cancer·Margaret A Knowles, Carolyn D Hurst
Mar 24, 2015·Trends in Immunology·Kristen E Pauken, E John Wherry
Aug 12, 2015·Proceedings of the National Academy of Sciences of the United States of America·Ariane HammitzschPaul Bowness
Sep 12, 2015·Cell·Dan R Littman
Jan 26, 2016·The Journal of Clinical Investigation·Jaclyn AndricovichAlexandros Tzatsos
Feb 6, 2016·Nature Medicine·Kimberly H Kim, Charles W M Roberts
Apr 23, 2016·Nature Communications·Isao KiiMasatoshi Hagiwara

❮ Previous
Next ❯

Citations

Nov 22, 2018·Nature Reviews. Molecular Cell Biology·Anushka Dongre, Robert A Weinberg
Apr 14, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Piao LiHong Qiu
Nov 2, 2019·Nature Reviews. Cancer·Elizabeth D WilliamsErik W Thompson
Jun 28, 2018·Clinical & Experimental Metastasis·Andrew D RedfernErik W Thompson
Sep 14, 2017·International Journal of Oncology·Yingxun LiuChen Huang
Jan 16, 2019·International Journal of Molecular Sciences·Sara Monteiro-ReisCarmen Jerónimo
Mar 12, 2020·Journal of Cell Communication and Signaling·Yang ZhengXiaomeng Song
Aug 19, 2017·Stem Cells International·Manuel Varas-GodoySebastián E Illanes
Apr 23, 2021·Journal of Molecular Histology·Reihaneh Alsadat MahmoudianMehran Gholamin

❮ Previous
Next ❯

Software Mentioned

Oncomine Research Addition
UCSC Xena Genome Browser
Xena browser
cBioPortal
Xena

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Alternative splicing

Alternative splicing a regulated gene expression process that allows a single genetic sequence to code for multiple proteins. Here is that latest research.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.